Abstract:The treatment options available for prostate cancer are limited because of its resistance to therapeutic agents. Thus, a better understanding of the underlying mechanisms of the resistance of prostate cancer will facilitate the discovery of more efficient treatment protocols. Human phosphatidylethanolamine-binding protein 4 (hPEBP4) is recently identified by us as an anti-apoptotic molecule and a potential candidate target for breast cancer treatment. Here we found the expression levels of hPEBP4 were positively correlated with the severity of clinical prostate cancer. Furthermore, hPEBP4 was not expressed in TRAIL-sensitive DU145 prostate cancer cells, but was highly expressed in TRAIL-resistant LNCaP cells, which show highly activated Akt. Interestingly, hPEBP4 overexpression in TRAILsensitive DU145 cells promoted Akt activation but inhibited ERK1/2 activation. The hPEBP4-overexpressing DU145 cells became resistant to TRAIL-induced apoptosis consequently, which could be reversed by PI3K inhibitors. In contrast, silencing of hPEBP4 in TRAIL-resistant LNCaP cells inhibited Akt activation but increased ERK1/2 activation, resulting in their sensitivity to TRAIL-induced apoptosis that was restored by the MEK1 inhibitor. Therefore, hPEBP4 expression in prostate cancer can activate Akt and deactivate ERK1/2 signaling, leading to TRAIL resistance. We also demonstrated that hPEBP4-mediated resistance to TRAIL-induced apoptosis occurred downstream of caspase-8 and at the level of BID cleavage via the regulation of Akt and ERK pathways, and that hPEBP4-regulated ERK deactivation was upstream of Akt activation in prostate cancer cells. Considering that hPEBP4 confers cellular resistance to TRAIL-induced apoptosis and is abundantly expressed in poorly differentiated prostate cancer, silencing of hPEBP4 suggests a promising approach for prostate cancer treatment. Prostate cancer is the most common malignancy and one of the leading causes of cancer mortality in men. The development of human prostate cancer has been viewed as amultistage process, involving the onset as small latent carcinoma of low histological grade to large metastatic lesion of higher grade. Unfortunately, chemotherapy and radiation therapy are not effective for prostate cancer patients. Therefore, a better understanding of molecular mechanisms for the resistance of prostate cancer cells to therapeutic agents will be useful to explore more efficient treatment protocols. Multiple signaling pathways govern the progression of prostate cancer, and the two most significant and well investigated pathways are the phosphatidylinositol 3-kinase (PI3K)3/Akt and MAPK pathways (1, 2).ThePI3K/Aktpathwaymediatessurvivalsignalsinandrogendependent and -independent prostate tumor cell lines, and controls the progression of prostate cancer to an androgenindependent state (1). The activation of ERK1/2 is detectable in premalignant lesions and/or early stage cancers; hence, it may play a role in the pathogenesis or early progression of prostate cancer (3, 4). It has been shown that activation of Akt and inactivation of ERK in high Gleason-grade prostate cancer, and importantly, increased Akt activation, alone or together with decreased ERK activation, is an excellent predictor of poor clinical outcome in prostate cancer (6). Therefore, overactivation of the Akt pathway is regarded as one of the reasons for resistance of prostate cancer to therapeutic agents, and targeting to inhibit Akt activationmay be beneficial in order to increase the therapeutic efficacy of human prostate cancer. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) acts through the pro-apoptotic TRAIL-R1/DR4 and TRAIL-R2/DR5 receptors, which leads to the cleavage and activation of caspase-8, resulting in BID cleavage, a Bcl-2 inhibitory protein, and triggering mitochondrial depolarization in tumor cells (7–9). TRAIL is currently being tested in clinical trials as an anticancer agent for barely detectable systemic cytotoxic effects. Recent studies have shown that Akt and ERK are all important regulators of TRAIL sensitivity in many cancers including prostate cancer (10–12). Akt phosphorylates specific * This work was supported in part by Grants from the National Natural Science Foundation of China (30600747, 30121002, 30490240), TsinghuaYue-Yuen Medical Sciences Fund (202400.005-02), the National Key Basic Research Program of China (2001CB510002), and the National High Biotechnology Development Program of China (2002BA711A01). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 These authors contributed equally to this work. 2 To whom correspondence should be addressed: Inst. of Immunology and National Key Laboratory of Medical Immunology, Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, China. Fax: 86-21-65382502; E-mail: caoxt@public3.sta.net.cn. 3 The abbreviations used are: PI3K, phosphatidylinositol 3-kinase; Akt/PKB, protein kinase B; ERK, extracellular signal-regulated kinase; PEBP, phosphatidylethanolamine-binding protein; PI, propidium iodide; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; TNF, tumor necrosis factor; FACS, fluorescent-activated signal sorting; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase. THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 282, NO. 7, pp. 4943–4950, February 16, 2007 © 2007 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.

Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration‐resistant prostate cancer cells to enzalutamide

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model

Targeting CPT1B as a potential therapeutic strategy in castration‐resistant and enzalutamide‐resistant prostate cancer

Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation

PLCε knockdown overcomes drug resistance to androgen receptor antagonist in castration‐resistant prostate cancer by suppressing the wnt3a/β‐catenin pathway

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment

Resists TRAIL-induced Apoptosis of Human Prostate Cancer Cells by Activating Akt and Deactivating ERK 1 / 2 Pathways *

Targeting the metabolic enzyme PGAM2 overcomes enzalutamide resistance in castration-resistant prostate cancer by inhibiting BCL2 signaling

Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway

Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death

Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7

Abstract 5151: Enzalutamide resistance results in immunosuppressive alterations in prostate tumor immune microenvironment

BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity

Abstract 3495: A kinome-wide CRISPR screen identifies CK1α as a novel target to overcome enzalutamide resistance of prostate cancer

Abstract A018: Pathways to enzalutamide resistance: An analysis of proteomic changes in enzalutamide-resistant prostate cancer cells

Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response

Data from Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer

Abstract 7270: Combination targeting of SKP2 and KDM5B induces senescence in castration-resistant prostate cancer cells via AKT signaling

Understanding the development of enzalutamide resistance based on a functional single-cell approach

Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis

Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation